Cardiff Oncology Inc Expects $0.24 Loss Per Share and 39.6% Decline in Quarterly Revenue in 2024

Summary

Cardiff Oncology Inc expects to report a loss of $0.24 per share for the period ending December 31, 2024, with quarterly revenue decreasing by 39.6% to a total of $94,170. The average analyst rating remains ‘buy’, with a 12-month median target price of $11.50, significantly above the last closing price of $4.56. Previous earnings reports have been mixed, with the most recent performance exceeding expectations by 24.3%.Reuters

Impact Analysis

This is a company-level event as it pertains specifically to Cardiff Oncology Inc’s projected financial performance. The anticipated loss and revenue decline might initially appear concerning, but the continued ‘buy’ rating and substantial target price suggest optimism about long-term prospects. The historical context indicates that Cardiff has previously outperformed expectations, which may temper negative investor reactions. Investors may see this as an opportunity to buy shares at a lower price, expecting future positive performance and potential price appreciation to the target level.Reuters